{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:56:02Z","timestamp":1754160962030,"version":"3.41.2"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Lower urinary tract symptoms are common in patients with neurodegenerative diseases and are important to recognize and treat to maintain quality of life. In this article, we focus on patients suffering from Parkinsons disease and atypical parkinsonism and the different onset and character of urinary symptoms in both groups. A diagnostic approach in primary health care, possible behavioral changes, and types of oral treatments are discussed. Further invasive treatments including botulinum toxin injections, sacral neuromodulation, and bladder augmentation are also discussed.<\/jats:p>","DOI":"10.61409\/v07240496","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:48:21Z","timestamp":1738644501000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Urinary disturbances in parkinsonism"],"prefix":"10.61409","author":[{"given":"Maria Feldborg Bruun","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Winge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Coyne KS, Wein AJ, Tubaro A et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103 Suppl;3:4-11. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08371.x","DOI":"10.1111\/j.1464-410X.2009.08371.x"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hunskaar S, Sandvik H. One hundred and fifty men with urinary incontinence. Scand J Prim Health Care. 1993;11(3):193-6. https:\/\/doi.org\/10.3109\/02813439308994829","DOI":"10.3109\/02813439308994829"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006;396(1):67-72. https:\/\/doi.org\/10.1016\/j.neulet.2005.11.012","DOI":"10.1016\/j.neulet.2005.11.012"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Winge K, Rasmussen D, Werdelin LM. Constipation in neurological diseases. J Neurol Neurosurg Psychiatry. 2003;74(1):13-9. https:\/\/doi.org\/10.1136\/jnnp.74.1.13","DOI":"10.1136\/jnnp.74.1.13"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Senard JM, Ra\u00ef S, Lapeyre-Mestre M et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584-9. https:\/\/doi.org\/10.1136\/jnnp.63.5.584","DOI":"10.1136\/jnnp.63.5.584"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Rojo A, Aguilar M, Garolera MT et al. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord. 2003;10(1):23-8. https:\/\/doi.org\/10.1016\/s1353-8020(03)00067-1","DOI":"10.1016\/S1353-8020(03)00067-1"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20(10):1255-63. https:\/\/doi.org\/10.1002\/mds.20527","DOI":"10.1002\/mds.20527"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry. 1990;53(6):480-6. https:\/\/doi.org\/10.1136\/jnnp.53.6.480","DOI":"10.1136\/jnnp.53.6.480"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"McDonald C, Rees J, Winge K et al. Bladder training for urinary tract symptoms in Parkinson disease: a randomized controlled trial. Neurology. 2020;94(13):e1427-e1433. https:\/\/doi.org\/10.1212\/WNL.0000000000008931","DOI":"10.1212\/WNL.0000000000008931"},{"key":"ref9","unstructured":"Bech S, Haugb\u00f8l S, Winge K. Differentialdiagnostiske udfordringer ved parkinsonisme. Ugeskr L\u00e6ger. 2017;179(33):V03170235"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42(6):1142-6. https:\/\/doi.org\/10.1212\/wnl.42.6.1142","DOI":"10.1212\/WNL.42.6.1142"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Reich SG, Savitt JM. Parkinson's disease. Med Clin North Am. 2019;103(2):337-350. https:\/\/doi.org\/10.1016\/j.mcna.2018.10.014","DOI":"10.1016\/j.mcna.2018.10.014"},{"key":"ref12","unstructured":"Backmann T, Mikkelsen T B, Juel K et al. Livet med Parkinson og behovet for rehabilitering - en unders\u00f8gelse af behov for fase-specifik rehabilitering ved Parkinsons sygdom i Danmark, REHPA, Videncenter for Rehabilitering og Palliation. 2020. https:\/\/www.rehpa.dk\/wp-content\/uploads\/2020\/08\/PReTT-til-TRYK.pdf. (5. jun 2024)"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Mathias CJ, Kimber J, Watson L, Muthane U. Is clonidine-growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease? J Neurol. 2002. 249(4):488-9. https:\/\/doi.org\/10.1007\/s004150200047","DOI":"10.1007\/s004150200047"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Winge K. Lower urinary tract dysfunction in patients with parkinsonism and other neurodegenerative disorders. Handb Clin Neurol. 2015;130:335-56. https:\/\/doi.org\/10.1016\/B978-0-444-63247-0.00019-5","DOI":"10.1016\/B978-0-444-63247-0.00019-5"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ito T, Sakakibara R, Yasuda K et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord. 2006;21(6):816-23. https:\/\/doi.org\/10.1002\/mds.20815","DOI":"10.1002\/mds.20815"},{"key":"ref16","unstructured":"Yao M, Simoes A. Urodynamic testing and interpretation. 2023. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562310\/ (24. okt 2024)"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Pavy-Le Traon A, Cotterill N, Amarenco G et al. Clinical rating scales for urinary symptoms in parkinson disease: critique and recommendations. Mov Disord Clin Pract. 2018;5(5):479-491. https:\/\/doi.org\/10.1002\/mdc3.12636","DOI":"10.1002\/mdc3.12636"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8-16. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.10.024","DOI":"10.1016\/j.parkreldis.2016.10.024"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sakakibara R, Panicker J, Finazzi-Agro E et al. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551-63. https:\/\/doi.org\/10.1002\/nau.22764","DOI":"10.1002\/nau.22764"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Brusa L, Petta F, Pisani A et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68(18):1455-9. https:\/\/doi.org\/10.1212\/01.wnl.0000260605.12506.86","DOI":"10.1212\/01.wnl.0000260605.12506.86"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-L\u00f3pez A, S\u00e1nchez-S\u00e1nchez A, Natera-Villalba E et al. SURINPARK: Safinamide for urinary symptoms in Parkinson's disease. Brain Sci. 2021;11(1):57. https:\/\/doi.org\/10.3390\/brainsci11010057","DOI":"10.3390\/brainsci11010057"},{"key":"ref22","unstructured":"Brostr\u00f8m S. Farmakologisk behandling af overaktiv bl\u00e6re - hvad skal jeg v\u00e6lge? Sundhedsstyrelsen, Rationel Farmakoterapi nr. 9. 2012. https:\/\/www.sst.dk\/da\/udgivelser\/2012\/Rationel-farmakoterapi-9-2012\/Farmakologisk-behandling-af-overaktiv-blaere---hvad-skal-jeg-vaelge"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Wang J, Zhou Z, Cui Y et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22-30. https:\/\/doi.org\/10.1002\/nau.23863","DOI":"10.1002\/nau.23863"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Schena G, Caplan MJ. Everything you always wanted to know about \u03b23-AR * (* But were afraid to ask). Cells. 2019;8(4):357. https:\/\/doi.org\/10.3390\/cells8040357","DOI":"10.3390\/cells8040357"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Przydacz M, Chlosta M, Dudek P et al. Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines. Cent European J Urol. 2020;73(4):498-505. https:\/\/doi.org\/10.5173\/ceju.2020.0283","DOI":"10.5173\/ceju.2020.0283"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Nitti V, Haag-Molkenteller C, Kennelly M et al. Treatment of neurogenic detrusor overactivity and overactive bladder with botox (onabotulinumtoxinA): development, insights, and impact. Medicine (Baltimore). 2023;102(S1):e32377. https:\/\/doi.org\/10.1097\/MD.0000000000032377","DOI":"10.1097\/MD.0000000000032377"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Baron M, Peyronnet B, Aubl\u00e9 A et al. Long-term discontinuation of botulinum toxin a intradetrusor injections for neurogenic detrusor overactivity: a multicenter study. J Urol. 2019;201(4):769-776. https:\/\/doi.org\/10.1016\/j.juro.2018.10.012","DOI":"10.1016\/j.juro.2018.10.012"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Martin S, Zillioux J, Goldman HB. Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review. Neurourol Urodyn. 2022;41(4):955-961. https:\/\/doi.org\/10.1002\/nau.24900","DOI":"10.1002\/nau.24900"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Smith MD, Tenison E, Hashim H et al. Neuromodulation for storage lower urinary tract symptoms in Parkinson disease: a\u202fsystematic review. Neuromodulation. 2022;25(8):1076-1085. https:\/\/doi.org\/10.1016\/j.neurom.2022.01.019","DOI":"10.1016\/j.neurom.2022.01.019"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:52:52Z","timestamp":1753692772000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V07240496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v07240496","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}